NewsTrending topic
Leukemia Vaccine Galinpepimut-S Meets Goal in Phase 3 AML Trial
On November 17, 2026, SELLAS said its leukemia vaccine galinpepimut-S improved overall survival in the phase 3 REGAL trial. What was reported, and what is not known yet.
Original commentary from the Cancer Explained editorial team.
Review status: AI-assisted, source checked. Not reviewed by a clinician. How we check pages
Sources last checked .

Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
What was announced
On November 17, 2026, SELLAS Life Sciences announced topline results from REGAL, a phase 3 trial of its vaccine galinpepimut-S (GPS) in acute myeloid leukemia (AML). The company said the vaccine met the trial's main goal: people who received it lived longer than people who received other available treatment.
The Washington Post also covered the result under the headline "Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs." The figures on this page come from the sources listed below.
This is a company announcement of topline results. It has not been published in a medical journal, and the full data have not been presented at a medical meeting.
The numbers reported so far
As reported by OncLive from the company's release:
- Median overall survival: 24.0 months with galinpepimut-S, against 14.7 months with the best available treatment.
- Hazard ratio for death: 0.59, with a two-sided P value of .035. A hazard ratio of 0.59 means a risk of death about 41 percent lower at any given point in time. That 41 percent is our arithmetic from the reported ratio. No confidence interval was given in the coverage we could read.
- When the analysis happened: this was the final analysis, triggered by the 80th death.
- Safety: most treatment-related side effects were grade 1 or 2, injection-site reactions were the most common, and the company said no new safety concerns appeared.
Overall survival means time from joining the trial until death from any cause. It is the main measure the trial was built around, and it is a hard measure to improve.
Who the trial studied
The registry record for REGAL (NCT04229979) describes a randomized, open-label phase 3 trial. "Open-label" means patients and doctors knew who got which treatment.
- Patients: adults with AML who had reached a second or later complete remission after second-line salvage therapy, and who were not candidates for an allogeneic stem cell transplant. A complete remission means leukemia can no longer be seen in the bone marrow; the registry requires fewer than 5 percent blast cells.
- Size: the registry lists 127 participants. The coverage we could read did not say how many were in each group.
- Treatment group: galinpepimut-S given by injection under the skin with an immune-boosting adjuvant (Montanide) and the growth factor GM-CSF, in a schedule of injections that continues for up to about three years.
- Comparison group: the investigator's choice of best available therapy, which could be observation, a hypomethylating drug (decitabine or azacitidine), venetoclax, or low-dose cytarabine.
The vaccine was given as maintenance, meaning after remission, to try to keep the leukemia from coming back. It is not a vaccine that prevents AML.
What is not known yet
- How many people were in each group, how many deaths occurred in each, and the confidence interval around the 0.59 ratio.
- Results for leukemia-free survival and for measurable residual disease, which were secondary measures.
- Whether the benefit held across subgroups, such as age or how the leukemia was first treated.
- How the open-label design, where everyone knew their treatment, may have affected care or follow-up.
- Whether the FDA will agree the result is enough. The company said it plans to meet with the FDA and is preparing a biologics license application, with submission expected in the first half of 2027.
What this does not mean
- It is not an approved treatment. Galinpepimut-S is investigational and cannot be prescribed. It is available only in clinical trials.
- It does not apply to everyone with leukemia. The trial studied one narrow group: AML in second or later remission, people not going to transplant. It says nothing about newly diagnosed AML or other leukemias.
- A topline announcement is not a final verdict. Companies report their own results first. The full data, reviewed by outside experts, may look different in the details.
- It is not treatment advice. If you or someone you love has AML, the choice of what comes after remission belongs to the person and their leukemia team.
If you want to know whether a trial might fit your situation, ask your care team, and see NCI's guide to clinical trials. For background, read our pages on acute myeloid leukemia and how AML is treated.
When to get checked
Call your cancer care team right away if you have AML or are in treatment and develop a fever of 100.4°F (38°C) or higher, bleeding that does not stop, new bruising, or severe weakness. Call 911 for trouble breathing, chest pain, or confusion that comes on suddenly.
Sources
- OncLive, Galinpepimut-S Improves OS in AML in Second or Later Remission (18 November 2026) — https://www.onclive.com/view/galinpepimut-s-improves-os-in-aml-in-second-or-later-remission
- ClinicalTrials.gov, NCT04229979, Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 — https://clinicaltrials.gov/api/v2/studies/NCT04229979
- SELLAS Life Sciences news release, 17 November 2026, via GlobeNewswire (as summarized by OncLive) — https://www.globenewswire.com/news-release/2026/11/17/3404429/0/en/sellas-life-sciences-announces-positive-pivotal-phase-3-regal-trial-data-showing-immunotherapeutic-cancer-vaccine-galinpepimut-s-gps-demonstrated-a-statistically-significant-and-cl.html
- NCI, Acute Myeloid Leukemia Treatment (PDQ), Patient Version — https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
- NCI, Clinical Trials Information for Patients and Caregivers — https://www.cancer.gov/about-cancer/treatment/clinical-trials
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Leukemia. The information below is general, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn more about leukemia
A news story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.